Kinnate Competitors

Delisted . USA . 
Stock . Kinnate Biopharma
KNTEDelisted Stock  USD 2.96  0.27  8.36%   
Kinnate Biopharma competes with ACELYRIN, INC, Windtree Therapeutics, Palisade Bio, Century Therapeutics, and Passage Bio; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Kinnate Biopharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Kinnate Biopharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Kinnate Biopharma competition on your existing holdings.
  
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Kinnate Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
2.962.962.96
Details
Intrinsic
Valuation
LowRealHigh
2.712.713.26
Details

Kinnate Biopharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Kinnate Biopharma and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Kinnate and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Kinnate Biopharma does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
GBIO
+ 0.88
PALI
GBIO
+ 0.8
SLRN
GRCL
+ 0.74
AMAM
PALI
+ 0.73
SLRN
GBIO
+ 0.62
WINT
IPSC
+ 0.6
PALI
  
High negative correlations   
GRCL
- 0.86
GBIO
GRCL
- 0.83
PALI
GBIO
- 0.74
AMAM
PALI
- 0.72
AMAM
FIXX
- 0.65
PASG
GRCL
- 0.63
WINT

Risk-Adjusted Indicators

There is a big difference between Kinnate Stock performing well and Kinnate Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Kinnate Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
AMAM  3.64  0.60  0.11 (1.44) 4.78 
(3.72)
 6.05 
(7.28)
 29.96 
SLRN  3.38 (0.48) 0.00  2.65  0.00 
 0.00 
 6.29 
(8.76)
 30.99 
WINT  6.38 (2.89) 0.00 (2.62) 0.00 
 0.00 
 11.43 
(18.48)
 63.85 
PALI  5.45 (0.57) 0.00 (3.81) 0.00 
 0.00 
 5.97 
(12.26)
 93.57 
IPSC  4.13 (0.47) 0.00 (0.91) 0.00 
 0.00 
 7.44 
(7.41)
 31.00 
PASG  6.35  0.54  0.06 (2.00) 6.92 
(7.53)
 12.07 
(11.86)
 84.39 
FIXX  2.82  0.16  0.03 (0.17) 3.52 
(3.25)
 5.77 
(5.61)
 19.43 
GBIO  3.91 (1.20) 0.00 (2.75) 0.00 
 0.00 
 6.36 
(8.20)
 20.32 
STOK  2.54 (0.15) 0.00  0.82  0.00 
 0.00 
 5.57 
(5.08)
 21.35 
GRCL  5.71  1.46  0.19 (0.89) 6.35 
(6.70)
 16.34 
(6.25)
 52.11 
All Fundamental Data

Kinnate Biopharma Competitive Analysis

The better you understand Kinnate Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Kinnate Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Kinnate Biopharma's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
KNTE AMAM SLRN WINT PALI IPSC PASG FIXX GBIO STOK
 8.36 
 2.96 
Kinnate
 4.73 
 15.73 
Ambrx
 4.73 
 3.32 
ACELYRIN,
 3.13 
 0.31 
Windtree
 3.51 
 1.77 
Palisade
 3.70 
 1.04 
Century
 1.54 
 0.66 
Passage
 5.83 
 1.09 
Homology
 3.74 
 1.11 
Generation
 1.60 
 11.06 
Stoke
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Slightly risky
Abnormally volatile
Very risky
Unstable
Extremely Dangerous
Very steady
Risky
Somewhat reliable
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Weak
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Dangerous
Average
Very High
Very High
Very High
Very High
Dangerous
Very High
Average
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Buy
Hold
Strong Buy
Strong Buy
Strong Buy
Not Available
Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Strong Sell
Strong Sell
Strong Sell
Sell
Strong Sell
Not Rated
Sell
Strong Sell
Current Ratio
23.3
4.7
N/A
2.47
2.59
17.79
9.23
8.44
17.93
10.46
Net Asset
173.6 M
146.98 M
742.69 M
32.41 M
14.05 M
360.69 M
150.54 M
306.12 M
374.76 M
228.34 M
EBITDA
(118.21 M)
(61.75 M)
(381.53 M)
(20.16 M)
(12.28 M)
(121.21 M)
(98.34 M)
(91.52 M)
(133.3 M)
(112.3 M)
Current Valuation
(25.71 M)
1.56 B
(222.73 M)
2.54 M
(2.43 M)
(51.68 M)
(18.25 M)
(27 M)
(16.85 M)
358.45 M
Price To Book
0.79
7.31
0.63
0.64
0.79
0.47
0.56
0.0414
0.71
2.56
Operating Margin
N/A
-483.51
N/A
N/A
N/A
-43.98
N/A
-78.85
-2.21
-6.13
Retained Earnings
(372.01 M)
(291.63 M)
(488.72 M)
(844.82 M)
(121.51 M)
(655.77 M)
(594.47 M)
(542.1 M)
(571.38 M)
(401.85 M)
Current Asset
N/A
N/A
N/A
40.79 M
N/A
N/A
144.91 M
48.82 M
N/A
N/A
Beta
1.34
-2.36
N/A
0.64
1.33
1.42
1.2
-0.11
2.82
0.95
Number Of Employees
84
87
135
N/A
9
152
58
7
174
110
Shares Outstanding
47.17 M
63.29 M
100.33 M
8.75 M
2.77 M
85.03 M
61.77 M
3.23 M
66.79 M
52.97 M
Cash Flow From Operations
(100.04 M)
(57.7 M)
(169.71 M)
(13.44 M)
(11.13 M)
(88.35 M)
(78.26 M)
(96.23 M)
(52.74 M)
(81.07 M)
Total Debt
3.17 M
11.98 M
1.19 M
16.83 M
369 K
48.17 M
26.29 M
1.32 M
97.89 M
2.06 M
Return On Equity
-0.56
-0.37
-0.42
-1.51
-1.1
-0.63
-0.64
-0.9
-0.86
-0.52
Z Score
19.38
85.23
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.34
-0.19
-0.33
-0.45
-0.59
-0.21
-0.34
-0.36
-0.19
-0.28
Number Of Shares Shorted
465.63 K
1.16 M
5.99 M
496.99 K
1.84 M
2.71 M
1.7 M
338.72 K
1.78 M
7.26 M
Book Value Per Share
3.66
3.85
5.29
5.9
18.3
2.31
2.03
22.65
1.57
4.38
Current Liabilities
N/A
N/A
N/A
11.07 M
N/A
N/A
3.09 M
8.27 M
N/A
N/A
Total Asset
173.6 M
146.98 M
742.69 M
32.41 M
14.05 M
360.69 M
150.54 M
306.12 M
374.76 M
228.34 M
Debt To Equity
0.014
0.088
N/A
0.95
0.23
0.12
0.11
0.14
0.27
0.026
Short Ratio
0.96
1.21
11.83
0.06
0.29
4.82
6.61
0.62
8.96
13.77
Target Price
2.36
28.5
10.0
7.0
30.33
8.33
8.0
1.5
7.5
22.5
Shares Owned By Institutions
82.58
97.91
99.45
0.59
3.57
61.11
59.68
46.75
82.93
95.4
Market Capitalization
124.99 M
1.77 B
333.08 M
4.92 M
5.25 M
88.43 M
40.58 M
3.02 M
74.14 M
585.82 M
Price To Earning
N/A
0.19
N/A
-0.05
0.16
86.08
N/A
-10.0
N/A
N/A
Price To Earnings To Growth
N/A
-0.15
N/A
N/A
N/A
0.26
N/A
21.38
N/A
0.27
Price To Sales
N/A
432.96
N/A
660.53
14.03
32.95
N/A
2.61
3.99
34.99
Net Income
(112.65 M)
(67.06 M)
(381.64 M)
(20.29 M)
(12.3 M)
(136.67 M)
(102.06 M)
(112.96 M)
(126.61 M)
(104.7 M)
Earnings Per Share
-2.78
0.42
-2.46
-19.03
-13.26
-1.83
-1.17
-35.1
-2.19
-2.08
Shares Owned By Insiders
0.15
2.09
8.03
0.27
1.88
28.06
0.49
9.2
14.51
4.6
Revenue
N/A
4.09 M
N/A
N/A
250 K
2.23 M
N/A
1.16 M
5.9 M
8.78 M
Working Capital
146.18 M
73.92 M
651.48 M
1.38 M
10.74 M
159.15 M
101.62 M
72.34 M
232.7 M
184.52 M
Cash And Equivalents
262.42 M
110.89 M
N/A
11.38 M
5 M
378.76 M
239.25 M
201.07 M
301.17 M
275.63 M
Cash Per Share
5.94
2.87
N/A
0.37
0.23
6.43
4.39
3.5
5.07
6.99
Gross Profit
N/A
7.4 M
N/A
(17.79 M)
N/A
5.2 M
N/A
(95.14 M)
N/A
12.4 M
Day Typical Price
3.05
15.54
3.25
0.32
1.75
1.06
0.64
1.07
1.09
11.17
Accumulation Distribution
0.0923
0.0675
0.0719
453826.0
0.0611
27307.38
47158.45
0.0727
0.0714
17704.64
Market Facilitation Index
0.3
1.08
0.24
N/A
0.11
N/A
N/A
0.08
0.08
0.0
Daily Balance Of Power
(0.90)
0.6574
0.625
(0.17)
0.5455
(0.44)
0.1667
0.75
0.5
(0.29)
Period Momentum Indicator
(0.27)
0.71
0.15
(0.01)
0.06
(0.04)
0.01
0.06
0.04
(0.18)
Rate Of Daily Change
0.92
1.05
1.05
0.97
1.04
0.96
1.02
1.06
1.04
0.98
Day Median Price
3.1
15.45
3.22
0.32
1.75
1.07
0.63
1.06
1.08
11.23
Price Action Indicator
(0.28)
0.64
0.17
(0.01)
0.055
(0.04)
0.035
0.06
0.05
(0.25)
Coefficient Of Variation
(19,184)
866.56
(1,017)
(347.38)
(1,940)
(1,210)
2035.87
2408.52
(407.72)
(2,471)
Mean Deviation
4.52
3.64
3.38
6.38
5.45
4.13
6.35
2.82
3.91
2.54
Jensen Alpha
(0.09)
0.5956
(0.48)
(2.89)
(0.57)
(0.47)
0.5416
0.1633
(1.20)
(0.15)
Total Risk Alpha
(0.19)
0.4427
(0.62)
(3.14)
(0.87)
(0.60)
0.2264
0.0407
(1.33)
(0.26)
Sortino Ratio
N/A
0.1051
N/A
N/A
N/A
N/A
0.0648
0.0296
N/A
N/A
Downside Variance
N/A
28.83
N/A
N/A
N/A
N/A
62.79
16.92
N/A
N/A
Standard Deviation
5.59
5.17
4.82
9.91
10.8
5.38
11.11
3.71
4.83
3.69
Kurtosis
(0.21)
2.95
2.53
7.23
26.16
2.55
21.42
0.7375
(0.42)
3.48
Potential Upside
8.7
6.05
6.29
11.43
5.97
7.44
12.07
5.77
6.36
5.57
Treynor Ratio
(0.02)
(1.44)
2.65
(2.62)
(3.81)
(0.91)
(2.00)
(0.17)
(2.75)
0.8151
Maximum Drawdown
22.4
29.96
30.99
63.85
93.57
31.0
84.39
19.43
20.32
21.35
Variance
31.27
26.73
23.24
98.21
116.64
28.92
123.42
13.76
23.28
13.58
Market Risk Adjusted Performance
(0.01)
(1.43)
2.66
(2.61)
(3.80)
(0.90)
(1.99)
(0.16)
(2.74)
0.8251
Risk Adjusted Performance
0.0044
0.1004
(0.07)
(0.22)
(0.03)
(0.06)
0.0484
0.0409
(0.19)
(0.02)
Skewness
0.1575
0.0614
(0.39)
1.18
3.88
1.06
3.68
(0.24)
0.3533
(0.03)
Semi Deviation
N/A
4.78
N/A
N/A
N/A
N/A
6.92
3.52
N/A
N/A
Information Ratio
(0.01)
0.1092
(0.11)
(0.29)
(0.05)
(0.09)
0.0462
0.0328
(0.25)
(0.05)
Value At Risk
(9.14)
(7.28)
(8.76)
(18.48)
(12.26)
(7.41)
(11.86)
(5.61)
(8.20)
(5.08)
Expected Short fall
N/A
(3.72)
N/A
N/A
N/A
N/A
(7.53)
(3.25)
N/A
N/A
Downside Deviation
N/A
5.37
N/A
N/A
N/A
N/A
7.92
4.11
N/A
N/A
Semi Variance
N/A
22.83
N/A
N/A
N/A
N/A
47.87
12.41
N/A
N/A

Kinnate Biopharma Competition Performance Charts

Five steps to successful analysis of Kinnate Biopharma Competition

Kinnate Biopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Kinnate Biopharma in relation to its competition. Kinnate Biopharma's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Kinnate Biopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Kinnate Biopharma's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Kinnate Biopharma, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Kinnate Biopharma position

In addition to having Kinnate Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run World Allocation Funds Thematic Idea Now

World Allocation Funds
World Allocation Funds Theme
Funds or Etfs investing in stocks, bonds, and cash of domestic markets as well as in markets of Canada, Japan, and Europe. The World Allocation Funds theme has 44 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize World Allocation Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Stocks Directory module to find actively traded stocks across global markets.

Other Consideration for investing in Kinnate Stock

If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Stocks Directory
Find actively traded stocks across global markets
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY